IF 5.2 3区医学

Vaccines Pub Date : 2025-09-22 DOI: 10.3390/vaccines13090991

Pablo Nogales-Altozano, Laro Gómez-Marcos, Ana Belén Carlón, Andrés Louloudes-Lázaro, Alicia Rivera-Rodríguez, Jaime Larraga, Pedro J Alcolea, Ana Alonso, Vicente Larraga, Verónica Martín, José M Rojas, Noemí Sevilla

{"title":"Heterologous DNA-Adenovirus Prime-Boost Strategy Expressing Bluetongue Virus VP2 and VP7 Proteins Protects Against Virulent Challenge.","authors":"Pablo Nogales-Altozano, Laro Gómez-Marcos, Ana Belén Carlón, Andrés Louloudes-Lázaro, Alicia Rivera-Rodríguez, Jaime Larraga, Pedro J Alcolea, Ana Alonso, Vicente Larraga, Verónica Martín, José M Rojas, Noemí Sevilla","doi":"10.3390/vaccines13090991","DOIUrl":"10.3390/vaccines13090991","url":null,"abstract":"Background/objectives: Bluetongue virus (BTV) is an emerging arbovirus causing significant economic losses in the ruminant industry. Current vaccines offer limited cross-protection against heterologous serotypes and do not enable differentiation between infected and vaccinated animals (DIVA). Subunit-based vaccines provide a potential DIVA-compatible solution. This study aimed to develop a vaccination protocol expressing BTV structural proteins VP7 or VP2 using antibiotic-resistance-free DNA plasmids and replication-defective adenovirus vectors.Methods: We evaluated homologous DNA prime-boost and heterologous DNA prime-adenovirus boost strategies in a murine model, assessing adaptive immune responses and protection against virulent BTV challenge.Results: The heterologous DNA-adenovirus prime-boost strategy expressing both antigens conferred full protection, preventing viremia, while homologous DNA-DNA prime-boost provided only partial protection. Both VP7 and VP2 elicited cellular and humoral immune responses, but the heterologous strategy significantly enhanced anti-BTV IgG, neutralizing antibody titers, and T cell activation. CD8+ T cell responses showed the strongest correlation with viral load reduction, suggesting that cellular immunity to conserved VP7 could serve as a platform for cross-protection against multiple BTV serotypes.Conclusions: These findings highlight the potential of heterologous DNA-adenovirus vaccination as an effective DIVA-compatible strategy for BTV control. By inducing strong and protective immune responses, this approach could improve disease surveillance and management, ultimately reducing the impact of BTV on livestock industries.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Biotechnology and the Development of Novel Human Vaccines. 生物技术的进展与新型人类疫苗的发展。

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-22 DOI: 10.3390/vaccines13090989

Ioanna Papadatou, Athanasios Michos

引用次数: 0

What Stage Are We at in the Development of Vaccines Against Tick-Borne Diseases? 针对蜱传疾病的疫苗研制目前处于什么阶段？

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-22 DOI: 10.3390/vaccines13090990

Weronika Stachera, Magdalena Szuba, Arya Taesung Kim, Subin Yu, Jaeuk Choi, Deborah Nzekea, Yen Ching Wu, Adrianna Brzozowska, Marcin Sota, Marianna Misiak, Monika Dybicz

引用次数: 0

Multilevel Analysis of Zero-Dose Children in Sub-Saharan Africa: A Three Delays Model Study. 撒哈拉以南非洲地区零剂量儿童的多水平分析：三延迟模型研究。

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-21 DOI: 10.3390/vaccines13090987

Charles S Wiysonge, Muhammed M B Uthman, Duduzile Ndwandwe, Olalekan A Uthman

{"title":"Multilevel Analysis of Zero-Dose Children in Sub-Saharan Africa: A Three Delays Model Study.","authors":"Charles S Wiysonge, Muhammed M B Uthman, Duduzile Ndwandwe, Olalekan A Uthman","doi":"10.3390/vaccines13090987","DOIUrl":"10.3390/vaccines13090987","url":null,"abstract":"Background: Zero-dose children represent a critical challenge for achieving universal immunization coverage in sub-Saharan Africa. This study applies the Three Delays Model to examine multilevel factors associated with zero-dose children.Methods: We analyzed data from 30,500 children aged 12-23 months across 28 sub-Saharan African countries using demographic and health surveys (2015-2024). Zero-dose status was defined as not receiving the first dose of diphtheria-tetanus-pertussis vaccine. Multilevel logistic regression models examined individual-, community-, and country-level determinants.Results: Overall, zero-dose prevalence was 12.19% (95% confidence interval: 11.82-12.56), ranging from 0.51% in Rwanda to 40.00% in Chad. Poor maternal health-seeking behavior showed the strongest association (odds ratio (OR) 12.00, 95% credible interval: 9.78-14.55). Paternal education demonstrated clear gradients, with no formal education increasing odds 1.52-fold. Maternal empowerment factors were significant: lack of decision-making power (OR = 1.23), financial barriers (OR = 1.98), and no media access (OR = 1.32). Low community literacy and low country-level health expenditure were associated with increased zero-dose prevalence. Substantial clustering persisted at community (19.5%) and country (18.7%) levels.Conclusions: Zero-dose children concentrate among the most disadvantaged populations, with maternal health-seeking behavior as the strongest predictor. Immediate policy actions should integrate antenatal care with vaccination services, target high-parity mothers, eliminate financial barriers, and increase health expenditure to 15% of national budgets.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Visual Detection of Malaria Parasite-Parasitized Erythroblasts in Peripheral Blood via Immunization-Based Model. 基于免疫模型的外周血疟疾寄生虫寄生红细胞视觉检测。

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-21 DOI: 10.3390/vaccines13090988

Kumpei Ito, Yuki S Tateishi, Takashi Imai, Shinya Miyazaki, Yukiko Miyazaki, Wataru Kagaya, Mai Nakashima, Miho Sase, Misato Yoshioka-Takeda, Chikako Shimokawa, Kyoko Hayashi, Kentaro Itokawa, Osamu Komagata, Ha Ngo-Thanh, Aoi Shimo, Tamasa Araki, Takeshi Annoura, Takashi Murakami, Hajime Hisaeda

{"title":"Visual Detection of Malaria Parasite-Parasitized Erythroblasts in Peripheral Blood via Immunization-Based Model.","authors":"Kumpei Ito, Yuki S Tateishi, Takashi Imai, Shinya Miyazaki, Yukiko Miyazaki, Wataru Kagaya, Mai Nakashima, Miho Sase, Misato Yoshioka-Takeda, Chikako Shimokawa, Kyoko Hayashi, Kentaro Itokawa, Osamu Komagata, Ha Ngo-Thanh, Aoi Shimo, Tamasa Araki, Takeshi Annoura, Takashi Murakami, Hajime Hisaeda","doi":"10.3390/vaccines13090988","DOIUrl":"10.3390/vaccines13090988","url":null,"abstract":"Background: Erythroblasts have recently been identified as host cells for malarial parasites, revealing a previously underappreciated host-parasite interaction. However, their extremely low abundance in peripheral blood has hindered progress, especially in elucidating the biological significance of parasitized erythroblasts (pEBs) in vivo.Methods: Here, we visualized pEBs in a murine model and established a method to increase their number in peripheral blood by immunizing mice with live Plasmodium yoelii 17XNL, followed by challenge with P. berghei ANKA.Results: Immunized mice were protected from cerebral malaria and survived longer, during which pEBs appeared in circulation and were detected using Giemsa-stained smears. All blood-stage parasite forms were identified within pEBs, including enucleating erythroblasts.Conclusions: This model enables in vivo/ex vivo analysis of pEB biology without bone marrow/spleen isolation, thus lowering technical/ethical barriers for the field.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Individualized mRNA Vaccines in Melanoma-Where Do We Stand? 黑色素瘤个体化mRNA疫苗研究进展如何？

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-21 DOI: 10.3390/vaccines13090986

Ioanna Gazouli, Dimitrios Bafaloukos, Christos Koutserimpas, George Samonis

引用次数: 0

Oral Vaccination with Aeromonas veronii Ghost Against Lethal Bacterial Infection in Cyprinus carpio. 维罗氏气单胞菌鬼影口服预防鲤鱼致命细菌感染。

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-20 DOI: 10.3390/vaccines13090985

Na Jiang, Zhihong Ma, Jinjing Zhang, Lin Luo, Xingchen Huo, Jufeng Jiang, Jian Gao, Jie Huang, Dongjie Shi

{"title":"Oral Vaccination with Aeromonas veronii Ghost Against Lethal Bacterial Infection in Cyprinus carpio.","authors":"Na Jiang, Zhihong Ma, Jinjing Zhang, Lin Luo, Xingchen Huo, Jufeng Jiang, Jian Gao, Jie Huang, Dongjie Shi","doi":"10.3390/vaccines13090985","DOIUrl":"10.3390/vaccines13090985","url":null,"abstract":"Background/objectives: Aeromonas veronii is a significant pathogen affecting aquatic animals and has the potential to infect humans. Vaccination remains the most effective strategy for preventing infections caused by this bacterial strain.Methods: This study aimed to validate the efficacy of bacterial ghosts as an oral vaccine by administering them to Cyprinus carpio and evaluating the resultant innate and acquired immune responses. Following immunization, the vaccinated Cyprinus carpio were exposed to a lethal dose of the wild-type bacterial strain to assess survival rates and relative protection efficiency.Results: Oral vaccination with bacterial ghosts led to the significant enhancement of lysozyme (LZM) and myeloperoxidase (MPO) activity in koi serum. It also resulted in the upregulation of cytokines, such as IL-2 and TNF-α, as well as an increase in both systemic (IgM) and mucosal (IgZs) antibody responses. The immunized group demonstrated reduced cumulative mortality following bacterial challenge. The relative percent survival in the vaccinated group reached as high as 87.50%.Conclusions: The oral immunization of Cyprinus carpio with A. veronii-derived bacterial ghosts confers substantial immune protection, providing a foundational basis for the development of novel vaccines against A. veronii.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlates of Meningococcal B Vaccination and Health Behavior Profiles Among MSM in China. 中国男男性行为者接种乙型脑膜炎球菌疫苗与健康行为的相关性

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-19 DOI: 10.3390/vaccines13090983

Rongyan Li, Qian Zou, Yi Zhou, Ye Zhang, Dan Wu, Xinyuan Zhang, Fengshi Jing, Jie Fan, Xi He, Weiming Tang

{"title":"Correlates of Meningococcal B Vaccination and Health Behavior Profiles Among MSM in China.","authors":"Rongyan Li, Qian Zou, Yi Zhou, Ye Zhang, Dan Wu, Xinyuan Zhang, Fengshi Jing, Jie Fan, Xi He, Weiming Tang","doi":"10.3390/vaccines13090983","DOIUrl":"10.3390/vaccines13090983","url":null,"abstract":"Background: Meningococcal B (MenB) vaccination offers protection against invasive meningococcal disease and moderate cross-protection against gonorrhea. However, little is known about coverage and behavioral correlates among men who have sex with men (MSM) in China. This study assessed self-reported MenB vaccination uptake and its associations with sociodemographic and behavioral factors.Methods: We conducted a nationwide cross-sectional survey among 1022 MSM recruited via community-based organizations and online platforms. Vaccination status and recent sexual behaviors were self-reported. Logistic regression identified correlates of uptake, and latent class analysis (LCA) examined behavioral profiles.Results: Participants had a mean age of 29.6 years; most were unmarried (87.7%) and nearly 90% had a college degree or above. Overall, 21.7% reported receiving MenB vaccination. Uptake was positively associated with condomless anal intercourse (aOR = 1.57, 95% CI: 1.08-2.31), group sex (occasionally: aOR = 1.63, 95% CI: 1.01-2.64; frequently: aOR = 3.86, 95% CI: 1.85-8.04), and female partners in the past six months (aOR = 3.69, 95% CI: 2.25-6.10). MSM with multiple casual male partners were less likely to be vaccinated (aOR = 0.55, 95% CI: 0.32-0.93). LCA identified heterogeneous subgroups; notably, the \"multi-partner and proactive\" group, with high pre-exposure prophylaxis against HIV infection awareness and frequent STI testing, showed low uptake (13.4%).Conclusions: MenB vaccination coverage among MSM in China remained suboptimal. Uptake differed across behavioral subgroups, underscoring the need for stratified, context-specific strategies to inform future vaccine introduction.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial. 基线抗sars - cov -2 IgG和对症状感染的保护：SCTV01E 3期随机试验的事后分析

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-19 DOI: 10.3390/vaccines13090984

Lixin Yan, Jiang Yi, Dongfang Liu, Jian Li, Adam Abdul Hakeem Baidoo, Liangzhi Xie

{"title":"Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial.","authors":"Lixin Yan, Jiang Yi, Dongfang Liu, Jian Li, Adam Abdul Hakeem Baidoo, Liangzhi Xie","doi":"10.3390/vaccines13090984","DOIUrl":"10.3390/vaccines13090984","url":null,"abstract":"Background: Following SARS-CoV-2 infection, the necessity of vaccination after natural infection remains uncertain. However, many asymptomatic individuals who test negative virologically may nevertheless receive vaccination without being aware of their prior infection. Investigating the implications for vaccine safety and efficacy is crucial. Methods: We analyzed the daily fluctuations in anti-SARS-CoV-2 IgG antibody levels during the enrollment period of a phase 3 randomized, double-blinded, placebo-controlled clinical trial of a tetravalent COVID-19 protein vaccine, SCTV01E. Additionally, we investigated the relationship between baseline IgG levels and their protection against COVID-19 in participants who received placebo. Results: The daily enrolled participants with different baseline IgG levels (<338 BAU/mL, 338-1000 BAU/mL, >1000 BAU/mL) showed dynamic changes with the enrollment date. Among participants with baseline IgG levels < 338 BAU/mL, vaccination conferred a relative protective efficacy of 69.15% (95% CI: 51.14-80.52%) against symptomatic SARS-CoV-2 infection compared with the control group. Conversely, in those with higher baseline IgG levels (≥338 BAU/mL), vaccination did not confer additional benefit. In the placebo group, the relative protection in participants with baseline IgG levels ≥ 338 BAU/mL was 93.79% (87.60%, 96.89%) compared to that of those with baseline IgG levels < 338 BAU/mL. The safety profile of SCTV01E in participants with baseline IgG ≥ 338 BAU/mL was comparable to that in participants with <338 BAU/mL, with favorable safety profiles. Conclusions: During the SCTV01E phase 3 clinical trial, an anti-SARS-CoV-2 IgG antibody IgG level of 338 BAU/mL was suitable for screening individuals in the early phase post-infection alongside virological tests. Vaccinating the infected population was safe and did not compromise efficacy. Clinical Trial: NCT05308576.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Hussain et al. Mind the Age Gap: Expanding the Age Window for mRNA Vaccine Testing in Mice. Vaccines 2025, 13, 370. 更正：Hussain等人。注意年龄差距：扩大小鼠mRNA疫苗测试的年龄窗口疫苗2025、13、370。

IF 5.2 3区医学

Vaccines Pub Date : 2025-09-19 DOI: 10.3390/vaccines13090982

Muattaz Hussain, Agata Ferguson-Ugorenko, Rebecca Macfarlane, Natalie Orr, Samuel Clarke, Michael J A Wilkinson, Linda Horan, Yvonne Perrie

引用次数: 0

Vaccines最新文献